Magnus Jaderberg
Chief Tech/Sci/R&D Officer presso Targovax Oy
Profilo
Magnus Jaderberg is currently working as a Principal at Karolinska Institutet, an Honorary Lecturer at King's College (Pennsylvania), a Principal at The Royal College of Physicians, and as the Chief Medical Officer at Targovax Oy.
Previously, he worked as the Chief Medical Officer-Europe at Bristol Myers Squibb Co. and as the Chief Medical Officer at Circio Holding ASA.
Posizioni attive di Magnus Jaderberg
Società | Posizione | Inizio |
---|---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Tech/Sci/R&D Officer | - |
King's College (Pennsylvania) | Corporate Officer/Principal | - |
Karolinska Institutet | Corporate Officer/Principal | - |
The Royal College of Physicians | Corporate Officer/Principal | - |
Precedenti posizioni note di Magnus Jaderberg
Società | Posizione | Fine |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
CIRCIO HOLDING ASA | Chief Tech/Sci/R&D Officer | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
CIRCIO HOLDING ASA | Health Technology |
Aziende private | 1 |
---|---|
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
- Borsa valori
- Insiders
- Magnus Jaderberg